Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9952W HIGH $8.98
Volume
365.73 K
Value Traded
33.77 M
Short % Float
25.74%
-11.01%Week
+11.76%1 Month
+42.86%3 Month
+82.69%6 Month
-38.1%5 Year
-79.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.69 B
EPS (TTM)
-1.04
P/E Ratio
-
Ent. Value
2.76 B
Total Shares
356.44 M
Float Shares
164.24 M
Insiders
54.13%
Institutions
39.73%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Precigen, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Precigen, Inc.
421Total events
5Upcoming
89Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneAdenoVerseEx-US Regulatory
FDA grants platform technology designation to AdenoVerse immunotherapeutic platform
▲Quarterly UpdateCorporate
Reported Q2 2026 financial results with net income of $20.1 million
▲Enrollment MilestonePAPZIMEOSApprovedTrial
PAPZIMEOS patient hub enrollment reached well over 500 patients
recurrent respiratory papillomatosis (RRP)source ↗
▲Exclusivity GrantedPAPZIMEOSApprovedIP / Competition
FDA granted PAPZIMEOS seven-year market exclusivity
recurrent respiratory papillomatosis (RRP)source ↗
▲EMA ValidationPAPZIMEOSApprovedEx-US Regulatory
EMA validated and is reviewing MAA for zopapogene imadenovec
recurrent respiratory papillomatosis (RRP)source ↗
▲EU Orphan DesignationPAPZIMEOSApprovedEx-US Regulatory
PAPZIMEOS granted orphan drug designation from European Commission
recurrent respiratory papillomatosis (RRP)source ↗
●Enrollment UpdatePAPZIMEOSApprovedTrial
Open-label redosing study of zopapogene imadenovec is currently enrolling
recurrent respiratory papillomatosis (RRP)source ↗
▲PublicationPAPZIMEOSApprovedPresentation
Expert position paper recommended PAPZIMEOS as first-line standard of care for adults with RRP
recurrent respiratory papillomatosis (RRP)source ↗
◆Enrollment UpdatePRGN-2012ApprovedTrial
Redosing study of zopapogene imadenovec in adults with RRP is currently enrolling
recurrent respiratory papillomatosis (RRP)source ↗
▲EMA ValidationPRGN-2012ApprovedEx-US Regulatory
EMA validated and is reviewing MAA for zopapogene imadenovec
recurrent respiratory papillomatosis (RRP)source ↗
●Trial InitiationPRGN-2009Trial
Multicenter Phase 2 trial of PRGN-2009 in combination with pembrolizumab is ongoing
recurrent/metastatic cervical cancersource ↗
▲Product LaunchPAPZIMEOSApprovedPost-Market
PAPZIMEOS net revenue of $53.1 million in Q2 2026, more than double prior quarter
recurrent respiratory papillomatosis (RRP)source ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
▲Oral PresentationPAPZIMEOSApprovedPresentation
Updated long-term durability data presented at ASCO 2026
recurrent respiratory papillomatosis (RRP)source ↗
▲FDA ApprovalPAPZIMEOSApprovedFDA Decision
FDA full approval for PAPZIMEOS
recurrent respiratory papillomatosis (RRP)source ↗
▲Exclusivity GrantedPAPZIMEOSApprovedIP / Competition
Seven-year market exclusivity granted by FDA
recurrent respiratory papillomatosis (RRP)source ↗
▲Exclusivity GrantedPAPZIMEOSApprovedIP / Competition
FDA grants orphan drug exclusivity for PAPZIMEOS for RRP through August 14, 2032
recurrent respiratory papillomatosis (RRP)source ↗
▲Other Regulator MilestonePAPZIMEOSApprovedEx-US Regulatory
CMS assigned permanent J-code J3404 to PAPZIMEOS effective April 1, 2026
recurrent respiratory papillomatosis (RRP)source ↗
◆Oral PresentationPresentation
Precigen to participate in virtual fireside chat with H.C. Wainwright
▲PublicationPAPZIMEOSApprovedPresentation
Expert consensus paper published in The Laryngoscope recommending PAPZIMEOS as first-line standard of care for RRP
recurrent respiratory papillomatosis (RRP)source ↗
◆Oral PresentationPresentation
Precigen presentation at 44th Annual J.P. Morgan Healthcare Conference
▲EMA ValidationPAPZIMEOSApprovedEx-US Regulatory
EMA validation of Marketing Authorization Application for PAPZIMEOS
recurrent respiratory papillomatosis (RRP)source ↗
▲Enrollment UpdatePAPZIMEOSApprovedTrial
Patient hub enrollment doubled since November 2025
recurrent respiratory papillomatosis (RRP)source ↗
▲Oral PresentationPAPZIMEOSApprovedPresentation
Long-term follow-up data presented at AAO-HNSF 2025 Annual Meeting
recurrent respiratory papillomatosis (RRP)source ↗
▲Debt Royalty FinancingCorporate
Up to $125 million non-dilutive credit facility with Pharmakon Advisors
▲Product LaunchPAPZIMEOSApprovedPost-Market
PAPZIMEOS available to prescribers and sales force deployment
recurrent respiratory papillomatosis (RRP) in adultssource ↗
◆PDUFA DatePRGN-2012ApprovedRegulatory Filing
PDUFA target action date set for August 27, 2025
recurrent respiratory papillomatosissource ↗
▲FDA ApprovalPAPZIMEOSApprovedFDA Decision
FDA approval of PAPZIMEOS for RRP
recurrent respiratory papillomatosis (RRP)source ↗
▲Product LaunchPAPZIMEOSApprovedPost-Market
Commercial launch of PAPZIMEOS
recurrent respiratory papillomatosis (RRP)source ↗
▲Primary Endpoint MetPAPZIMEOSApprovedClinical Data
Pivotal study met primary efficacy endpoint (reduction in surgeries)
recurrent respiratory papillomatosis (RRP)source ↗
▲Long Term DataPAPZIMEOSApprovedClinical Data
2-year durability data: 15 of 18 complete responders maintained response
recurrent respiratory papillomatosis (RRP)source ↗
▲FDA ApprovalPAPZIMEOSApprovedFDA Decision
FDA full approval of PAPZIMEOS for RRP
recurrent respiratory papillomatosis (RRP)source ↗
▲Product LaunchPAPZIMEOSApprovedPost-Market
Commercial launch and promotion of PAPZIMEOS begins
recurrent respiratory papillomatosis (RRP)source ↗
▲FDA ApprovalFDA Decision
FDA approval of Precigen's HPV-specific immunotherapy for adults with RRP
recurrent respiratory papillomatosis (RRP)source ↗
▲FDA ApprovalPAPZIMEOSApprovedFDA Decision
PAPZIMEOS approved by FDA for adults with recurrent respiratory papillomatosis
recurrent respiratory papillomatosis (RRP)source ↗
▲Product LaunchPAPZIMEOSApprovedPost-Market
PAPZIMEOS commercially available in the US
recurrent respiratory papillomatosis (RRP)source ↗
◆PDUFA DatePRGN-2012ApprovedRegulatory Filing
PDUFA target action date for PRGN-2012 in RRP
recurrent respiratory papillomatosis (RRP)source ↗
◆Product LaunchPRGN-2012ApprovedPost-Market
Potential commercial launch in second half of 2025
recurrent respiratory papillomatosissource ↗
◆Oral PresentationPresentation
2025 International RRP Awareness Day live event and webcast
recurrent respiratory papillomatosissource ↗
Past FDA Catalysts and PDUFA Decisions
How PGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-08-15 | PRGN-2012 (zopapogene imadenovec) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$201M
Pipeline Value
$366M
Commercial Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 74%
Small Cap(rank 487 of 658)
Percentile Rank
Precigen, Inc. faces pipeline headwinds (28/100), with $704M risk-adjusted pipeline value, led by AG019- Low Dose in Diabetes type1 (Phase 1), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $85.7M x 4.3 = $366M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Papzimeos | $75M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AG019- Low Dose Monoclonal antibodyCompletedNCT03751007 | Diabetes type1 | Phase 1 | COMPLETED | 45 | Oct 13, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every PGEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PRGN-2012 BreakthroughPriorityAccelerated+1 | recurrent respiratory papillomatosis | Phase 1/2 | 2024-06-03 | complete response: 51% (18 out of 35); surgical interventions reduction: 86% (30 out of 35); median pre treatment surgeries: 4; median post treatment surgeries: 0; median duration of follow up: 20 monthsRead More | Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response · Phase 1/2 pivotal study met the primary safety and efficacy endpoints · · 51% (18 out of 35) of patients achieved Complete Response, requiring no...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Thomasian Harry Jr.Officer (Chief Financial Officer) | Option | 10,744 268,993 held | $4.72 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1.7 % (30.8 %) | 36.58 M | 6.42 M |
PGEN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how PGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPGEN News
PGENPrecigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Precigen, Inc. announced that the FDA granted platform technology designation to its AdenoVerse platform, which is utilized in its product PAPZIMEOS. This designation allows for accelerated development of future therapies and enhances the potential for early FDA engagement. The platform is adaptable for various indications, including HPV-related cancers.
Read more →PGEN▲ +5.5%on this news
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
Precigen reported strong financial results for Q2 2026, with PAPZIMEOS revenue exceeding $53 million, more than double the previous quarter. This growth led to the company's first quarterly profitability. The FDA granted PAPZIMEOS seven years of market exclusivity, and over 500 patients are now enrolled in treatment. The company anticipates reaching cash flow break-even by the end of 2026.
Read more →PGEN▲ +8.3%on this news
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. announced it will release its second quarter 2026 financial results and provide business updates on August 4, 2026. A conference call will be held at 4:30 PM ET to discuss these results. The company focuses on innovative precision medicines for difficult-to-treat diseases and has a strong commitment to advancing scientific breakthroughs.
Read more →PGEN▲ +16.5%on this news
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation celebrate the third annual RRP Awareness Day, emphasizing the importance of patient voices in understanding recurrent respiratory papillomatosis (RRP). This event comes after the FDA's approval of Precigen's HPV-specific immunotherapy, the first treatment for adults with RRP. The campaign aims to raise awareness and support for those affected by this debilitating disease.
Read more →PGEN▼ -5.1%on this news
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen, Inc. announced updated long-term data for PAPZIMEOS at the 2026 ASCO Annual Meeting. The therapy, recently granted FDA approval and seven-year market exclusivity, demonstrates significant durability in treating recurrent respiratory papillomatosis (RRP). With 83% of patients showing ongoing responses, PAPZIMEOS is positioned as the new standard of care for RRP, traditionally managed through repeated surgeries.
Read more →PGENPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen, Inc. announced that the FDA has granted orphan drug exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) for treating adults with recurrent respiratory papillomatosis (RRP). This exclusivity, effective until August 14, 2032, follows the full approval of PAPZIMEOS in August 2025, making it the first approved therapy for RRP. The exclusivity enhances the product's market protection and revenue potential.
Read more →PGENPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen, Inc. announced its participation in two upcoming investor events, including a virtual fireside chat with J.P. Morgan and the Goldman Sachs 47th Annual Global Healthcare Conference. CEO Helen Sabzevari will represent the company at both events, highlighting its commitment to advancing precision medicines. Details about the events can be found on Precigen's website.
Read more →PGEN▲ +10.8%on this news
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. reported strong financial results for Q1 2026, driven by the successful launch of PAPZIMEOS, the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The company recognized $21.6 million in net revenue from PAPZIMEOS and is optimistic about future growth. Despite a net loss of $7.9 million, Precigen is focused on expanding its market presence and advancing its pipeline.
Read more →PGEN▼ -5.7%on this news
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. announced it will release its first quarter 2026 financial results on May 13, 2026. The company will hold a conference call at 4:30 PM ET to discuss these results. Precigen specializes in precision medicines aimed at treating difficult diseases, with a focus on immuno-oncology and other therapeutic areas.
Read more →PGEN▼ -11.4%on this news
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen, Inc. announced that its President and CEO, Helen Sabzevari, along with Chief Commercial Officer Phil Tennant, will participate in a virtual fireside chat with H.C. Wainwright on March 31, 2026. This event aims to discuss the company's advancements in precision medicine and its robust pipeline targeting difficult-to-treat diseases. Details for the event can be found on Precigen's website.
Read more →PGEN▲ +25.5%on this newsshared move
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen, Inc. reported its full year 2025 financial results, highlighting the FDA approval and launch of PAPZIMEOS, which has gained strong traction among physicians and patients. The company noted a significant increase in revenues driven by PAPZIMEOS sales, despite a notable rise in net loss due to non-cash items. The company anticipates reaching cash flow break-even by the end of 2026.
Read more →PGENPrecigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
Precigen, Inc. is set to announce its full year 2025 financial results and provide business updates on March 25. The announcement will be accessible through a conference call, with details available on the company's website. The press release includes a cautionary statement regarding forward-looking statements, highlighting potential risks and uncertainties related to the company's business strategies and the commercialization of their product, PAPZIMEOS. Stakeholders are advised to review the risk factors outlined in the company's latest Annual Report.
Read more →PGENNew Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. announced that a new expert consensus paper recommends PAPZIMEOS (zopapogene imadenovec) as the first-line treatment for adults with recurrent respiratory papillomatosis (RRP). This marks a significant shift from traditional surgical interventions to a therapy that targets the underlying HPV infection. The consensus, authored by 16 leading physicians, emphasizes the importance of early treatment and provides a clear management approach for RRP.
Read more →PGEN▼ -9.9%on this news
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for...
Precigen has announced the successful commercialization of PAPZIMEOS, the first and only FDA-approved treatment for recurrent respiratory papillomatosis (RRP). The company has reported rapid adoption across medical centers and expanded payer access since its launch. With strong safety and efficacy data, PAPZIMEOS is projected to establish itself as the preferred first-line treatment for RRP. Furthermore, Precigen is focused on global expansion, as indicated by the European Medicines Agency validating its Marketing Authorization Application.
Read more →PGEN▲ +8.9%on this news
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. announced that its CEO, Dr. Helen Sabzevari, will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. Additionally, she will participate in a fireside chat at the Biotech Showcase on January 12, 2026. These events highlight Precigen's focus on advancing precision medicines.
Read more →PGEN▲ +25.6%on this news
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen, Inc. reported its third-quarter 2025 financial results, highlighting the FDA approval of PAPZIMEOS, the first treatment for adults with recurrent respiratory papillomatosis (RRP). The company noted strong demand and early interest in the therapy, which aims to address the root cause of RRP. However, financial results showed a significant increase in expenses and a notable net loss.
Read more →PGENPrecigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen, Inc. will announce its third quarter 2025 financial results and provide business updates on November 13, 2025. A conference call is scheduled for the same day at 4:30 PM ET, accessible via specific dialing instructions. The company focuses on innovative precision medicines for difficult-to-treat diseases.
Read more →PGENPrecigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. announced long-term follow-up results showing durable responses to PAPZIMEOS, the first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Presented at the AAO-HNSF 2025 Annual Meeting, the data indicate that 51% of patients achieved complete response, eliminating the need for surgeries. The therapy is well-tolerated and represents a breakthrough in RRP treatment.
Read more →PGENPrecigen Announces Up to $125 Million Non-Dilutive Financing
Precigen, Inc. has announced a credit facility agreement providing up to $125 million in non-dilutive financing, aimed at enhancing its balance sheet and supporting the commercialization of its immunotherapy, PAPZIMEOS. This funding will also facilitate potential international market expansion and the pursuit of pediatric and HPV-related indications. The financing reflects Precigen's strategic growth objectives as it transitions into a commercial entity.
Read more →PGENPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen, Inc. announced its participation in two virtual fireside chats hosted by Cantor and H.C. Wainwright. The discussions will focus on the recent FDA approval of a therapy for recurrent respiratory papillomatosis. Key executives from Precigen will represent the company during these events, which are accessible via their website.
Read more →About Precigen, Inc.
Headquarters20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876
BIOPHARMAWATCH ELITE PLUS
Trade the next PGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime